MEK抑制剂联合靶向程序性死亡1及程序性死亡配体1的免疫调节抗体在Kras/p53驱动肺癌中延长生存
本研究在Kras/Trp53驱动的小鼠肺癌模型中,用MEK抑制剂曲美替尼联合抗PD-1或抗PD-L1单抗治疗,联合治疗较单药协同增强抗肿瘤反应和生存获益,并增加瘤内CD8+与CD4+ T细胞、减少MDSC。
要点
- PKL驱动肺癌中髓源性抑制细胞(MDSC)较正常肺显著增多,PD-L1在肿瘤细胞尤其MDSC高表达。
- 曲美替尼联合抗PD-1或抗PD-L1单抗较单药协同增强抗肿瘤反应与生存获益。
- 联合治疗使瘤内CD8+和CD4+ T细胞显著增加,CD11b+/Gr-1high MDSC尤其Ly6Ghigh多形核MDSC减少。
核心结论
- 作者认为,靶向MEK抑制剂与免疫治疗联合的协同作用为难以靶向的Kras/p53驱动肺癌提供了潜在治疗途径。
研究设计与样本
- 采用Trp53FloxFlox;KrasG12D/+;Rosa26LSL-Luciferase/LSL-Luciferase(PKL)基因工程小鼠,经气管内递送腺病毒Cre重组酶诱导自体肺肿瘤。
- 用质谱流式和流式细胞术表征荷瘤肺的肿瘤浸润免疫细胞。
- 在PKL介导的免疫健全同系和转基因肺癌小鼠模型中,单用MEK抑制剂曲美替尼及联合抗PD-1或抗PD-L1单抗治疗,评估肿瘤生长与生存结局。
- 用流式细胞术和免疫组化评估脾和肿瘤内免疫细胞群。
主要发现
- PKL驱动肺肿瘤中髓源性抑制细胞(MDSC)较无肿瘤小鼠正常肺显著增多。
- PD-L1在肺肿瘤细胞尤其MDSC中呈高阳性表达。
- 在同系和转基因肺癌模型中,曲美替尼联合抗PD-1或抗PD-L1单抗较单药治疗协同增加抗肿瘤反应和生存获益。
- 联合治疗使同系模型中肿瘤浸润CD8+和CD4+ T细胞显著增加,CD11b+/Gr-1high MDSC尤其Ly6Ghigh多形核MDSC减少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: This study aimed to characterize the tumor-infiltrating immune cells population in Kras/tumor protein 53 (Trp53)-driven lung tumors and to evaluate the combinatorial antitumor effect with MEK inhibitor (MEKi), trametinib, and immunomodulatory monoclonal antibodies (mAbs) targeting either programmed death -1 (PD-1) or programmed cell death ligand 1 (PD-L1) in vivo. METHODS: Trp53FloxFlox;KrasG12D/+;Rosa26LSL-Luciferase/LSL-Luciferase (PKL) genetically engineered mice were used to develop autochthonous lung tumors with intratracheal delivery of adenoviral Cre recombinase. Using these tumor-bearing lungs, tumor-infiltrating immune cells were characterized by both mass cytometry and flow cytometry. PKL-mediated immunocompetent syngeneic and transgenic lung cancer mouse models were treated with MEKi alone as well as in combination with either anti-PD-1 or anti-PD-L1 mAbs. Tumor growth and survival outcome were assessed. Finally, immune cell populations within spleens and tumors were evaluated by flow cytometry and immunohistochemistry. RESULTS: Myeloid-derived suppressor cells (MDSCs) were significantly augmented in PKL-driven lung tumors compared to normal lungs of tumor-free mice. PD-L1 expression appeared to be highly positive in both lung tumor cells and, particularly MDSCs. The combinatory administration of MEKi with either anti-PD-1 or anti-PD-L1 mAbs synergistically increased antitumor response and survival outcome compared with single-agent therapy in both the PKL-mediated syngeneic and transgenic lung cancer models. Theses combinational treatments resulted in significant increases of tumor-infiltrating CD8+ and CD4+ T cells, whereas attenuation of CD11b+/Gr-1high MDSCs, in particular, Ly6Ghigh polymorphonuclear-MDSCs in the syngeneic model. CONCLUSIONS: These findings suggest a potential therapeutic approach for untargetable Kras/p53-driven lung cancers with synergy between targeted therapy using MEKi and immunotherapies.
引用
- Lee JW, Zhang Y, Eoh KJ, et al. The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer. J Thorac Oncol. 2019. PMID: 30771521. doi:10.1016/j.jtho.2019.02.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。